Key Takeaways
- Tyson Foods (TSN) shares surged 4.5% after the company reported better-than-expected Q3 earnings and sales, subsequently raising its 2025 outlook.
- ON Semiconductor (ON) delivered Q2 2025 adjusted earnings per share in line with estimates and beat revenue forecasts, though its Q3 revenue guidance was mixed and adjusted EPS guidance had a lower end below estimates.
- The US Dollar is perceived to be at risk due to potential policy shifts influenced by political decisions, according to a Bloomberg report.
- Brazilian economists have slightly revised their 2025 and 2026 economic forecasts, including minor adjustments to GDP growth and inflation expectations, while maintaining the year-end 2025 interest rate at 15.00%.
- BofA Global Research reduced its price target for Moderna (MRNA) to $24 from $25, citing slightly lower value expectations.
Tyson Foods (TSN) delivered a robust performance in its third quarter of 2025, sending its shares up 4.5%. The meat processing giant reported sales of $13.88 billion, surpassing analyst estimates of $13.55 billion. Adjusted earnings per share also significantly beat expectations, coming in at $0.91 against an estimated $0.78.
Following these strong results, Tyson Foods (TSN) raised its 2025 outlook, indicating increased confidence in its future performance. The company now anticipates full-year adjusted operating income between $2.18 billion and $2.38 billion, with sales growth projected at +2% to +3%. Capital expenditures for the fiscal year are now seen up to $1.08 billion.
In the semiconductor sector, ON Semiconductor (ON) reported its Q2 2025 earnings, with adjusted EPS matching estimates at 53 cents. Revenue for the quarter reached $1.47 billion, slightly exceeding the estimated $1.45 billion.
Looking ahead, ON Semiconductor (ON) provided mixed guidance for Q3. The company projects Q3 revenue to be between $1.47 billion and $1.57 billion, with the higher end surpassing the $1.5 billion estimate. However, its Q3 adjusted EPS guidance of 54 cents to 64 cents has a lower end that falls below the estimated 58 cents.
On the macroeconomic front, the US Dollar is facing potential headwinds. Reports indicate that the dollar, along with other US assets, is vulnerable to risks stemming from political moves to select policymakers. This suggests market sensitivity to potential shifts in economic leadership and policy direction.
Meanwhile, Brazilian economists have provided updated forecasts for the nation's economy. The year-end 2025 interest rate is expected to remain at 15.00%, while the Brazilian Real is predicted to hold steady at 5.60 per dollar by the end of 2025. Annual inflation for 2025 is now slightly lower at 5.07% (down from 5.09%), and for 2026, it's projected at 4.43% (a minor decrease from 4.44%).
GDP growth expectations for Brazil have also seen minor adjustments. Economists now predict 2025 GDP growth at 2.23%, and the 2026 GDP growth forecast has been slightly reduced to 1.88% from 1.89% previously. These adjustments reflect ongoing recalibrations of the economic outlook within the region.
Finally, in the biotechnology space, BofA Global Research has revised its stance on Moderna (MRNA). The firm reduced its price target for the pharmaceutical company to $24 from $25, citing slightly lower value expectations for the stock.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.